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Abstract
Background: Patients with end-stage renal disease (ESRD) commonly suffer from severe fatigue, which strongly
impacts their quality of life (QoL). Although fatigue is often attributed to disease- and treatment characteristics,
research also shows that behavioural, psychological and social factors affect perceived fatigue in dialysis patients.
Whereas studies on fatigue in other chronic patient groups suggest that psychological or psychosocial interventions
are effective in reducing fatigue, such interventions are not yet available for ESRD patients on dialysis treatment. The
objective of this study is to examine the efficacy of a psychosocial intervention for dialysis patients aimed at reducing
fatigue (primary outcome) and improving QoL (secondary outcome). The intervention consists of counselling sessions
led by a social worker. The implementation process and patients’ and social workers’ expectations and experiences
with the intervention will also be evaluated.
Methods/Design: This study follows a mixed-methods design in which both quantitative and qualitative data will be
collected. A multi-centre, randomised controlled trial (RCT) with repeated measures will be conducted to quantitatively
assess the efficacy of the psychosocial intervention in reducing fatigue and improving QoL in ESRD patients. Additional
secondary outcomes and medical parameters will be assessed. Outcomes will be compared to patients receiving
usual care. A sample of 74 severely fatigued dialysis patients will be recruited from 10 dialysis centres. Patients
will be randomly assigned to the intervention or control group. Outcomes will be assessed at baseline, post
intervention/16 weeks, and at three and six-month follow-ups. A qualitative process evaluation will be conducted
parallel to/following the effectiveness RCT. Interviews and focus groups will be conducted to gain insight into
patients’ and social workers’ perspectives on outcomes and implementation procedures. Implementation fidelity
will be assessed by audio-taped and written registrations. Participatory methods ensure the continuous input of
experiential knowledge, improving the quality of study procedures and the applicability of outcomes.
Discussion: This is the first mixed method study (including an RCT and qualitative process evaluation) to examine
the effect and implementation process of a psychosocial intervention on reducing fatigue and improving QoL in
ESRD patients on dialysis treatment.
Trial registration: NTR5366, The Netherlands National Trial Register (NTR), registered August 26, 2015.
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Background
End-stage renal disease (ESRD) is a common chronic
illness with an increasing incidence and prevalence [1, 2].
In the Netherlands, over 16,000 patients require renal
replacement therapy due to severe kidney failure [3].
Although renal transplantation is the most preferred
treatment [4, 5], many patients cannot profit from this
option because of the donor shortage [5, 6] or medical
ineligibility for receiving a donor kidney [7, 8]. Conse-
quently, many ESRD patients depend on dialysis treat-
ment. In the Netherlands, around 6,500 ESRD patients
receive either haemodialysis or peritoneal dialysis treat-
ment [9]. Although dialysis treatment is life-saving, the
burdens of treatment are substantial and the therapy
only replaces 10–15 % of normal renal function [10].
Dialysis patients experience multiple enduring health
problems, of which fatigue is one of the most frequent
complaints [11–14]. The prevalence of (severe) fatigue
in dialysis patients ranges from 60–97 % [15, 16].
Fatigue is known as a subjective, unpleasant symptom
that can vary from tiredness to exhaustion, which inter-
feres with individuals’ ability to function in their normal
(physical and mental) capacity [17–19]. Fatigue limits
patients’ daily activities and independence, is often per-
ceived as a source of stress and is commonly associated
with reduced quality of life (QoL) [12, 13, 17]. Fatigue
in patients on dialysis is often attributed to disease and
treatment characteristics like anaemia, inflammation,
medication, dialysis intensity and frequency. Except for
Erythropoietin (EPO) injections to prevent anaemia, no
medication is known to affect/reduce feelings of fatigue
[20–22]. Although fatigue is often perceived as a physio-
logical side-effect of the chronic illness [12], research
shows that fatigue is not only grounded in physiological
factors. Fatigue seems to be caused by a complex inter-
action of biological processes, psychosocial phenomena
and behavioural manifestations [19]. Previous research
identified various behavioural, psychological and social
factors influencing fatigue in long-term dialysis patients
such as anxiety, stress, depression, sleep disorders, sub-
stance use, physical inactivity and (lack of) social support
[12]. Another study also highlighted the complex charac-
ter of fatigue in ESRD patients [17]. The authors made a
distinction between physical, cognitive and affective
fatigue, and identified various physiological, sociodemo-
graphic, psychological, behavioural and dialysis-related
factors to affect those various dimensions of fatigue.
Non-pharmalogical interventions targeted at behavioural,
psychological, cognitive and social factors, may potentially
be successful in decreasing fatigue in dialysis patients.
Studies on fatigue in patients with cancer [23–28], chronic
pain [29], chronic fatigue syndrome [30, 31], brain injury
[32] and muscular diseases [33, 34], suggest that such
psychological or psychosocial interventions are effective
in reducing fatigue that is caused by multiple interact-
ing factors. As far as we know, the literature does not
describe (evidence-based) psychological or psychosocial
interventions to reduce fatigue in ESRD patients. This
can be seen as a deficiency, since such interventions
may, based on other populations and causes of fatigue,
also be effective in reducing the experienced fatigue of
patients on dialysis.
The primary objective of this study is to investigate
the efficacy of a psychosocial intervention on the reduc-
tion of fatigue provided to patients on dialysis treatment,
compared to dialysis patients receiving usual care. Sec-
ondary objectives are to study the efficacy of the inter-
vention on improving the QoL and to investigate the
possible mediating and moderating effects of coping style,
illness cognitions and perceptions, catastrophizing thoughts,
feelings of depression, feelings of control and mastery,
and social support. A randomised controlled trial (RCT)
will be conducted to achieve these objectives. Next to the
RCT, a process evaluation will be conducted to gain an in-
depth understanding of both patients’ and professionals’
expectations of, and experiences with the psychosocial
intervention and its implementation. In addition, the de-
gree to which the intervention is implemented as intended
(implementation fidelity) will be evaluated [35–37].
Methods/Design
Design and setting
This study follows a mixed method design in which both
quantitative and qualitative methods will be applied for
data collection. The study involves a two-arm, multi-
centre RCT involving patients with ESRD undergoing a
dialysis treatment (either haemodialysis or peritoneal
dialysis). Patients will be randomly assigned to either the
intervention group (usual treatment and psychosocial
counselling by a social worker in the dialysis depart-
ment, aimed at reducing fatigue) or the control group
(usual treatment). Intervention efficacy will be quantita-
tively measured (repeated measures/self-report question-
naires/medical records) (Fig. 1). A qualitative process
evaluation will be conducted to gain insight into pa-
tients’ and professionals’ perspectives on outcomes and
implementation procedures. Both interviews and focus
groups will be applied for data collection. The study will
be conducted at both academic and non-academic dialysis
centres in the Netherlands. The aim is to include a
maximum of 10 centres in total.
Research team and advisory group
Research team
The study will be conducted by a team of three re-
searchers of the VU University Medical Centre (VUmc)
and two patient research partners who are experiential
experts in the field of kidney diseases/dialysis [38]. One
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them is a female patient (aged 48) suffering from kidney
disease, the second one is a father (aged 66) of a patient
who has been on dialysis treatment before transplan-
tation. Both patient research partners are equal members
of the research team and will participate in research
activities throughout all study phases (research set-up,
data collection and data analysis).
The surplus value of involving patient research partners
in scientific research has been increasingly acknowledged.
The experiential knowledge of patients complements
the scientific perspective of academic researchers and
contributes to the quality of research in various ways. It
helps to assure that research is grounded in relevant clin-
ical needs and targeted to patient-relevant outcomes, it can
enhance study design and practicability, it improves data
interpretation and it strengthens dissemination [39–42].
Advisory group
An advisory group consisting of patients, partners of
renal patients and professionals will monitor the study
and will be asked for input and feedback throughout all
study phases. Participants are five patients/relatives (mem-
bers of the Kidney Patients Association Netherlands -
NVN), two social workers and a nephrologist. The ad-
visory group will contribute to the quality of the study
and applicability of outcomes by providing input from
both patient and professional perspectives.
Patient recruitment
In collaboration with the research team, the Dutch Asso-
ciation for Social Workers in Nephrology has informed
its members about the opportunity to participate in this
multi-centre study. Dialysis centres sign in to participate
on a voluntary base. The local recruitment of patients
within the participating centres will begin after formal
approval is obtained by the head of the department, the
local ethics committee and/or the board of directors. The
social workers of the participating centres will be involved
in the pre-screening and recruitment of patients at their
centre (see inclusion and exclusion criteria below). They
will be asked to identify all potential participants that fit
the trial criteria within their patient population and to
(randomly) invite suitable patients to participate in the
study. The VUmc research team will provide a flyer and
patient information letter to all participating centres in
order to assure provision of identical study information
to patients. The flyers and letters will be handed to the
patients by the local social workers.
If a patient wants to participate, (after verbal consent)
contact details will be sent to the first research executive
Fig. 1 Study design
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[WB], who will inform patients about the study proce-
dures, answer questions and do a final check on inclu-
sion and exclusion criteria. Subsequently, the first
researcher will request that the patients fill out and
return the Checklist Individual Strength (CIS-fatigue)
questionnaire [43] in order to assess the perceived level
of fatigue. If the score is ≥ 35, the final inclusion criter-
ion is met. Patients will be informed about the survey re-
sults personally by phone, since we know from a former
study that patients do not appreciate written communi-
cation about inclusion and exclusion [34]. After obtai-
ning written informed consent and completion of the
baseline measurement, participants will be randomly
assigned to either the control or intervention group.
Sample size
The sample size calculation will be based on examining
the difference between the psychosocial intervention ver-
sus usual care on the primary outcome ‘subjective ex-
perience of fatigue’ (four repeated measurements) [43].
Thirty-seven patients will be needed in each condition,
assuming a significance of 5 % (two-tailed) and power of
80 % in detecting a clinically relevant change of eight
points on the primary outcome variable [25, 44]. We ex-
pect a drop-out rate of 30 % based on an unpublished
study by Dialysis Centre Groningen in 2011 (14 % mor-
tality, 5 % kidney transplantation, 11 % remaining).
Inclusion criteria
– Adult patients (age ≥ 18), male or female, who
undergo day dialysis (haemodialysis (HD), Peritoneal
Dialysis (PD), at home, a hospital or a dialysis centre);
– Experiencing (severe) fatigue (score CIS-fatigue
scale ≥ 35);
– Being able to walk/move for at least 10 min with or
without a supporting device such as a walking stick;
– Having a sufficient understanding of the Dutch
language in order to participate in counselling,
(group) interviews and fill out the questionnaires
adequately.
Exclusion criteria
– Dialysis during the night (since it is assumed that
patients on day dialysis experience more severe
fatigue compared to patients on night dialysis);
– Participation in other studies or treatments aimed at
reducing fatigue;
– Treatment by a psychologist or psychiatrist (for
severe psychiatric problems such as depression,
psychosis, personality disorders or schizophrenia);
– Alcohol or drug addiction.
Furthermore, social workers will be asked to take into ac-
count the dialysis vintage (minimum of three months) and
dialysis stability when pre-screening patients for the study.
Randomisation
Patients who meet the trial criteria and give informed
consent to participate in the study will be assigned to
either the intervention or the control group. Patients in
the control group will receive usual treatment. Patients
in the intervention group will receive a protocolled
psychosocial intervention provided by a social worker.
Computer-generated block randomisation will be per-
formed, ensuring the equal (1:1) allocation of patients to
either the intervention or control group at each partici-
pating centre. To ensure concealment, the block sizes
will not be disclosed. The allocation procedure is per-
formed by an independent research colleague who is
not involved in the study. The researcher [WB] will in-
form patients about the allocation outcome and subse-
quent study procedures. For ethical reasons, and if
desired, patients allocated to the control group will be
offered the opportunity to participate in the interven-
tion group after the third measurement. Due to the
nature of the intervention neither participants nor so-
cial workers can be blinded to allocation. Data entry
will be performed by a research assistant who is not
informed about group allocation.
Study intervention
Usual care versus psychosocial intervention
Patients in the control and the intervention group will
all receive usual care, which may include dialysis treat-
ment, medication and a nutritional regimen. The scope
of usual psychosocial care will be assessed at each partici-
pating centre. To prevent co-intervention bias, patients
participating in other studies or treatments aimed at redu-
cing fatigue will be excluded. Patients will not be restricted
in any activities. Any significant changes in health status
and/or treatment will be monitored throughout the study.
Patients assigned to the intervention group will receive
face to face psychosocial counselling directed to redu-
cing and managing fatigue. Patients will be involved in
4–6 individual protocolled counselling sessions (45 min
each) over a period of 16 weeks, and will perform several
practical (home) assignments/exercises. The sessions will
be given by a local social worker who is already employed
at the participating dialysis centre.
Intervention protocol
The intervention protocol has been developed by the
VUmc research team, of which one of the members
works as a health psychologist [KS]. The protocol is
partly based on pre-existing interventions that have
already been proven effective in the treatment of fatigue
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in other patient groups [45–47]. Previous research into
the perpetuating factors of (chronic) fatigue in patients
with chronic diseases in general [18, 19] and kidney dis-
eases in particular [12, 17] also provided valuable input
for protocol development, as well as a (yet unpublished)
qualitative interview study on the subjective experience
of fatigue in ESRD patients. This qualitative study was
initiated by the VUmc research team, and was conducted
prior to protocol development.
The protocol consists of eight modules, addressing
various behavioural, psychological, cognitive and social
aspects that influence fatigue. These factors encompass
sleep-wake rhythm and sleep hygiene routines, physical
activity, energy distribution, dysfunctional cognitions
with respect to fatigue, social support (communication,
needs and boundaries), catastrophizing thoughts and
worrying. Additional file 1 gives an extended overview of
the content of the intervention modules.
Intervention instruction for social workers
All involved social workers will be visited by a member
of the VUmc research team for instruction on how to
use the protocol. Prior to the instruction visit, a digital
version of the intervention protocol will be provided.
The instruction involves a brief explanation of the eight
modules, the method of module selection, counselling
procedures and the use of registration forms. Social
workers will also be informed about background, main
aims and study procedures. All participating professionals
are experienced in working with intervention protocols
and psychosocial counselling. During the study, a member
of the research team will be available to answer questions
about the protocol and counselling procedures.
Intervention procedures
Because of the variability in influencing factors of fatigue
in ESRD patients, counselling will be customised to each
patient individually. A certain procedure will, however,
be followed. After the patient has returned the baseline
measurement (see data collection), the social worker will
be informed by the research team and commissioned to
start the intervention. The social worker will invite the
patient to an intake session in which they jointly will
assess and decide which modules are most appropriate.
A decision aid is provided in the intervention protocol.
A maximum of three to four modules will be selected,
which will be addressed in 4–6 individual counselling
sessions of about 45 min each. Each module will include
one or more (take-home) exercise(s). The patient and
social worker agree on the timing and location of the
subsequent counselling sessions and whether a partner
or relative will participate in (a selection) of the sessions.
Data collection and management
This study will follow a mixed method design in which
both quantitative and qualitative data will be collected.
Quantitative measurements
To determine the effects of the intervention on the short-
and long-term, repeated quantitative measurements will
be conducted (four survey measurements over a period
of 13 months). These surveys will be completed by the
participants in both the intervention and control groups.
The primary outcome will be fatigue severity, mea-
sured by a subscale of the CIS-fatigue [43]. The secon-
dary outcome will be quality of life (kidney disease
specific), as measured by the KDQOL [48]. Question-
naires on coping style, illness cognitions/perceptions,
catastrophizing thoughts, depression, social support
and overall perceptions of mastery and control will be
included since these outcomes may be potential moder-
ating or mediating factors. In addition, various medical
parameters and demographics will be studied as poten-
tial modifiers. All outcome measures and assessment
instruments are listed in Table 1.
For each individual in the intervention group, mea-
surements will be obtained prior to the start of the study
period (T0 - baseline), immediately after the interven-
tion period of 16 weeks (T1 - post- treatment), three
months after the intervention period (T2 – short-term
follow-up) and nine months after the intervention period
(T3 – long-term follow-up). For patients participating in
the control group, measurements will be obtained ac-
cording to the same time frame (baseline; + 16 weeks; +
three months; + six months). (Participants will be able
to decide themselves how and when they fill out the
questionnaires (online/paper-pencil; at the dialysis centre/
at home). The overall duration of the study will be
13 months for each participant (in both intervention
and control group).
Qualitative process and effect evaluation
Besides quantitatively measuring intervention effects,
understanding the determinants of intervention success
or failure, and insight into the nature of the interven-
tion delivery is essential [37, 49–51]. Therefore, we will
perform a qualitative evaluation of both the process
and perceived effects parallel to/following the effective-
ness RCT [52].
Interviews and focus groups Individual interviews and
focus groups will be conducted to gain insight into pa-
tients’ and social workers’ expectations of, and experi-
ences with the intervention.
Approximately 15 patients who are assigned to the
intervention group will be invited for a semi-structured
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interview about attitudes and expectations regarding the
intervention (prior to the start of the intervention). After
the post-intervention measurement (T1), again, a subset
of 15 (different) patients will be invited for an interview
to assess their experiences with the intervention. Several
additional topics will be explored such as the nature of
the relationship with the (medical) social worker, (chan-
ged) attitudes regarding fatigue and future health/fatigue
expectations. Purposeful, maximum variation selection
will be applied in order to explore attitudes from a broad
range of participants (taking into account variation in
demographics, treatment and treatment history).
Interviews will take 60–90 min and will take place at a
time and location that best suits the patients. In addition,
10 patients will be invited to a focus group discussion to
share experiences, validate and deepen issues generated
from the interviews, and discuss suggestions to improve
the protocol. The duration of this focus group will depend
on the capacity of the participating patients, but will not
exceed 2.5 h (including breaks).
All participating social workers will be interviewed about
their expectations regarding the utility and effectiveness of
the intervention protocol. After finishing the last interven-
tion session with the last participating patient, they will be
interviewed about their experiences and asked to evaluate
the intervention protocol. The semi-structured interviews
will take place at the dialysis centre or by phone, and will
take approximately 30 min. After the study period, 8–10
(medical) social workers will be invited to a two-hour
focus group in order to exchange experiences, deepen
issues derived from the interviews and discuss potential
improvements of the protocol.
Both interviews and focus groups will be guided by a
pre-defined topic list, which will be discussed within the
VUmc research team and members of the advisory
group in advance. After approval of participants, all in-
terviews and focus groups will be audio-taped and
transcribed verbatim. Written interview reports will be
sent back to interview and focus group participants to
validate findings and improve credibility [53, 54].
Gained insights from both interviews and focus groups
will be used to improve the intervention protocol and
treatment feasibility, and to determine facilitators and
barriers to the successful engagement of both patients
and professionals.
Implementation fidelity To assess the implementation
fidelity of the intervention, all social workers will be
asked to audio-tape one of the counselling sessions held
with the second or third patient to whom they offer the
intervention. In order to collect a variety in recorded
sessions they will be asked to record the second or third
session, under the pre-condition that patients provide
written informed consent for audio-tapings. The research
executive will collect all audio-tapings and assess whether
the modules are offered according to the protocol
guidelines and face to face instruction by using a pre-
constructed observation checklist.
All social workers will also be asked to provide general
information about the dialysis population at their centre
and the total number of patients who are eligible,
decline and agree to participate. Social workers will be
asked to provide registrations for each participating
patient on the number and duration of counselling
Table 1 Measures and instrumentation
Instrumentation T0 T1 T2 T3
Primary outcome measures
Fatigue severity Checklist Individual Strength (CIS-fatigue) [43] x x x x
Secondary outcome measures
Quality of life Kidney Disease and Quality of Life Short Form (KDQOL-SF) [48] x x x x
Mediating/moderating variables
Social support Social Support Inventory (SSL-I + SSL-D) [58] + subscale Utrechtse Coping Lijst (UCL) [59] x x x x
Illness cognitions Illness Cognition Questionnaire (ICQ) [60] x x x x
Illness perceptions Illness Perception Questionnaire (IPQ-R) [61]: subscale emotional representation x x x x
Coping Cognitive Emotion Regulation Questionnaire (CERQ) [62] x x x x
Catastrophizing thoughts Fatigue Catastrophizing Scale (J-FCS) [63, 64] x x x x
Mastery Mastery Scale [65] x x x x
Depression Patient Health Questionnaire: Depression (PHQ-9) [66] x x
General effect modifiers
Demographic variables Self-report: age, gender, education, ethnicity, social status, employment x
Medical history and comorbidity Self-report: treatment, treatment frequency, transplantability x
Medical parameters Medical records: sleep medication, Epo, Hb, Urea, Creatinine, Protein, Albumin, CRP, weight, height x x
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sessions, the involvement of partners or relatives, drop-
out rates and reasons for drop-out. Registration forms
will be provided prior to the beginning of the trial.
Data management and privacy procedures All privacy
sensitive data (any information relating to an identified
or identifiable natural person) will be handled according
to the rules of protecting personal data (Personal Data
Protection Act/Wet Bescherming Persoonsgegevens). All
identifying information of participants will be coded and
de-personalised. Data will be stored in a secured project
file on the VUmc network. Access to the study data will
be restricted to involved research members, who all
signed a privacy statement.
Signed informed consent forms and returned coded/
anonymized questionnaires will be stored in a locker sep-
arately from study records that link to participant identify-
ing codes. Only the first responsible researcher [WB] has
access to these documents. Data entry will be performed
by a research assistant. Data integrity will be assured by
random consistency checks/re-entry of data. Audio taped
records of interviews/focus groups will be removed after
transcripts are provided. Archived electronic data will be
kept for a maximum of ten years, informed consent forms
for a maximum of five years, in line with the policy guide-
lines of the Quality Committee of the EMGO+ institute
(http://www.emgo.nl/kc/). Collected data will be processed
anonymously in publications and reports, preventing iden-
tification of individual participants.
Data analysis
Descriptive statistics for outcome measures will be pre-
sented. A paired t-test will be used to investigate statis-
tical significant differences in the effects (primary and
secondary outcomes) between intervention and control
groups. Statistical significance will be defined as p ≤ 0.05.
Statistical analyses will be performed using the SPSS sys-
tem for Windows, version 22.0. A detailed analysis plan
will be developed in collaboration with a statistical
expert. This plan will also address the analysis of po-
tential effect modifiers and confounders, and further
exploratory analyses.
Qualitative data will be subjected to a thematic ana-
lysis [55, 56]. Themes recurring from the data (interview
and focus group transcripts) will be categorised and
coded. The research team will meet on a regular basis
and discuss emerging themes throughout the research
process. Preliminary findings will be discussed with the
members of the advisory group.
The quantitative outcomes will be related to, and inte-
grated with the qualitative findings to determine corres-
pondence and discrepancies in perceived and measured
effects. The advisory group will be actively involved in
discussing findings and final conclusions.
Treatment modification
Any adverse events reported by participants or observed
by social workers will be monitored. If trial participation
would lead to, or worsen, health related problems, con-
tinuation and/or ancillary care will be discussed with the
patient, (medical) social worker and treating specialist.
Discussion
As far as we know, this study will be the first (mixed
method) study (including an RCT and qualitative process
evaluation) to consider the effect of a psychosocial in-
tervention on reducing fatigue and improving QoL in
patients with ESRD on dialysis.
This study will have several strengths. First, the mixed
method design of this study will allow for the integra-
tion of quantitative and qualitative findings, enhancing
our understanding of intervention effects and imple-
mentation processes. Second, involving an advisory
group and patient research partners will contribute to
the overall quality of research and practical applicability
of outcomes.
Existing psychological or psychosocial interventions to
reduce fatigue in other patient groups often comprise
cognitive behavioural therapy (CBT) provided by health
psychologists/therapists [33, 44]. However, a randomised
trial study [57] showed that counselling and CBT were
equivalent in effect for patients with chronic fatigue in
primary care. The psychosocial intervention in this study
will be provided by social workers employed at the pa-
tient’s dialysis department. Besides cost efficiency, in-
volving social workers will be the best option for various
reasons. Whereas a care relationship between patients
and social workers often already exists, and social workers
are familiar with patients’ background and illness history,
we expect this to be of added value in customising the
intervention to each patient individually. We also expect
that, for patients, the threshold to participate in counsel-
ling sessions with a social worker will be lower than the
participation in psychological therapy with a psychologist
they are not familiar with.
A potential limitation is that, by involving a various
group of social workers to implement the intervention,
treatment bias may occur. This will partly be countered
by allocating an equal number of participants in both
intervention and control groups at each participating
centre. Furthermore, potential confounding effects will
be explored by the assessment of implementation fidelity
and exploring contextual dynamics by interviews with
both patients and social workers.
Counselling sessions with a social worker, performing
(home) exercises and filling out questionnaires, will
require certain effort from patients participating in the
intervention group. However, we expect that, in the
end, these burdens will outweigh the expected gains of
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reduced fatigue and improved QoL. Both patient re-
search partners and members of the advisory group will
be consulted about their ideas on how to reduce bur-
dens for participants as much as possible and how to
promote retention. A member of the advisory board
emphasised that it may be difficult to keep patients mo-
tivated to change when they are fatigued. She suggested
paying extra attention when giving patients feedback on
progress and preliminary results of efforts during the
intervention period. This comment will be emphasised
in the intervention instructions for social workers.
This study will help to gain insight into the effective-
ness of a psychosocial intervention on reducing fatigue
in ESRD patients and improving their quality of life. If
the implementation of the intervention is shown to be
effective, the protocol will be made available to hospitals
and dialysis centres that are interested in offering psy-
chosocial counselling to their patient population.
Additional file
Additional file 1: Intervention modules. A schematic overview in
which the content and main aims of each intervention module are
described. (DOCX 26 kb)
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